COR-1167 is entering Phase 2 clinical trial for the treatment of Worsening Heart Failure after obtaining promising Phase 1 data, while the Phase 1 of COR-1389 is ongoing for the treatment of Obesity and Right Heart Failure.
Philip Janiak, Corteria’s CEO said:“The robust preclinical data, together with the emerging clinical data, strengthen our confidence as we move into Phase 2 and expand our footprint in cardiometabolic diseases.”
Full PR is available here :https://corteriapharma.com/wp-content/uploads/2025/07/250721-Corteria-CRF2-trials-EN.pdf